Purpose: This is a randomized trial to evaluate the efficacy and safety of a new type of medication in Ulcerative Colitis. This medication (Duvakitug) is an anti-TL1A inhibitor which decreases both fibrosis and inflammation for patients with IBD. The medication is given as an injection every 2 weeks. The study will last up to 4 years. In early trials, this drug has shown great efficacy for patients who have Crohn’s Disease and Ulcerative Colitis. All costs (study meds, lab work, procedures) are covered by the sponsor. Patients will be compensated for time and travel.
Our staff would be happy to review the details of the study with you.
Qualifications:
You are 18 to 80 years old
Have a confirmed diagnosis of Ulcerative Colitis
Have not had removal of your colon or a current ostomy
Have tried and failed at least 1 prior treatment for your Ulcerative Colitis
Sanofi STARSCAPE1 and STARSCAPE2 - CROHN'S DISEASE Fundor: Sanofi
A clinical research study testing a new injectable treatment for Crohn’s Disease, with study-related care provided at no cost.
PIs: Dr. Meena Bewtra, MD, MPH, PhD and Nicole Belle
Purpose: This is a randomized trial to evaluate the efficacy and safety of a new type of medication in Crohn’s Disease. This medication (Duvakitug) is an anti-TL1A inhibitor which decreases both fibrosis and inflammation for patients with IBD. The medication is given as an injection every 2 weeks. The study will last up to 4 years. In early trials, this drug has shown great efficacy for patients who have Crohn’s Disease and Ulcerative Colitis. All costs (study meds, lab work, procedures) are covered by the sponsor. Patients will be compensated for time and travel.
Our staff would be happy to review the details of the study with you.
Qualifications:
You are 18 to 80 years old
Have a confirmed diagnosis of Crohn’s Disease
Have not had removal of your colon or a current ostomy
Have tried and failed at least 1 prior treatment for your Crohn’s Disease